Literatur
- 1
Amado R G. et al .
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal
Cancer.
JCO.
2008;
26
1626-1634
- 2
Di Leo A. et al .
Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients
with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients.
Proc Am Soc Clin Oncol JCO.
2007;
25
(suppl)
, abstr 1011
- 3
Escudier B. et al .
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma:
a randomised, double-blind phase III trial.
The Lancet.
2007;
370
2103-2111
- 4
Geyer C E. et al .
Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic
and updated efficacy data.
Proc Am Soc Clin Oncol JCO.
2007;
25
(suppl)
, abstr 1035
- 5
Hudes G. et al .
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma.
N Engl J Med 2007.
;
356
2271-81
- 6
Llovet J. et al .
Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of
a Phase III randomized placebo-controlled trial (SHARP trial).
Proc Am Soc Clin Oncol JCO.
2007;
25
(suppl)
, abstr LBA1
- 7
Manegold C. et al .
Randomised, double-blind multicentre phase III study of bevacizumab in combination
with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent
non-squamous non-small cell lung cancer (NSCLC): BO17704.
Proc Am Soc Clin Oncol JCO.
2007;
25
(suppl)
abstr LBA751
- 8
Miller K. et al .
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer.
New England Journal of Medicine.
2007;
357
2666-2676
- 9
Nördlinger B. et al .
Final results of the EORTC Intergroup randomized phase III study 40 983 [EPOC] evaluating
the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable
colorectal cancer liver metastases.
Proc Am Soc Clin Oncol JCO.
2007;
25
(suppl)
abstr LBA5
- 10
Perez E A. et al .
Efficacy and Safety of Ixabepilone (BMS-247 550) in a Phase II Study of Patients With
Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine.
JCO.
2007;
(10)
3407-3414
- 11
Sandler A. et al .
Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer.
N Engl J Med 2006.
2006;
355
2542
- 12
Slotman B.
A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive
disease small cell lung cancer after a response to chemotherapy (EORTC 08 993 - 22
993).
Proc Am Soc Clin Oncol JCO.
2007;
25
(suppl)
abstr 4
- 13
van Cutsem E. et al .
Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in
the first-line treatment of patients with metastatic colorectal cancer (mCRC): The
CRYSTAL trial.
Proc Am Soc Clin Oncol JCO.
2007;
25
abstr 4000
- 14
Cutsem. et al .
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With
Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal
Cancer.
JCO.
2007;
25
1658-1664
- 15
Vermorken J. et al .
Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added
to first line platinum based therapy - Results of a randomized phase III (Extreme)
study.
Proc Am Soc Clin Oncol JCO.
2007;
25
(suppl)
abstr 6091
Priv.-Doz. Dr. med. H. J. Stemmler
Medizinische Klinik und Poliklinik III, Klinikum der LMU München, Standort Großhadern
Marchioninistraße 15
81377 München
Telefon: 089/7095-0
Fax: 089/7095-5574
eMail: Joachim.Stemmler@med.uni-muenchen.de
